The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised of a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.

Methods for processing and or removing organic residuals and or impurities from a solgel-derived bioactive glass-ceramic and compositions comprising solgel-derived bioactive glass-ceramics processed using these methods, are described.

A formulation of foam thermosensitive hydrogel includes a thermosensitive hydrogel including synthetic polymeric material. The thermosensitive hydrogel has properties of changing phase from liquid to solid in high temperature and changing phase from solid to liquid in low temperature. The foam thermosensitive hydrogel having a predetermined surface tension is formed after mixing the thermosensitive hydrogel with air. The foam thermosensitive hydrogel has properties of increased volume and being semisolid. After injecting the foam thermosensitive hydrogel into a human body, the foam thermosensitive hydrogel changes phase form liquid to solid after temperature rises above LCST. The foam thermosensitive hydrogel injected into the human body becomes a solid, physical barrier between an injured site and surrounding tissue, thereby preventing adhesion from forming in the human body. A method of manufacturing foam thermosensitive hydrogel is also provided.

Super-soft foam materials, optionally for use as medical dressings, are provided. The pads are made of a foam prepared from NCO-terminated prepolymers in combination with an aqueous phase including fatty alcohols and alkyl polysaccharides. The foam may optionally contain at least one medicinal agent.

The invention relates, generally, to porous absorbent materials which are suitable for packing antrums or other cavities of the human or animal body. More particularly, it relates to hydrophilic biodegradable foams, which may be used e.g. in the form of a plug or tampon, for instance for controlling bleeding, wound closure, prevent tissue adhesion and/or support tissue regeneration. The invention provides an absorbent foam, suitable for packing antrums or other cavities of the human or animal body, comprising a biodegradable synthetic polymer, which polymer preferably comprises —C(O)—O—groups in the backbone of the polymer, for instance polyurethane and/or polyester units combined with polyethers.

Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and
wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 μg of LL-37 applied per cm.sup.2 of wound area, and/or below about 26.7 μg of LL-37 applied per cm.sup.2 of wound area, per day of treatment.

The present invention relates to a powder type hemostatic composition and method for preparing the same, and more specifically, to powder aggregate having porosity obtained by combining powder of biocompatible hemostatic material with a binder and a method for preparing the same, and a powder type hemostatic composition which comprises the powder aggregate and shows improved hemostatic performance as compared with simple powder hemostatic agents, and can be used to a large surface area for hemostasis, or to narrow, thin or other sites to which approach for hemostasis is difficult.

The invention relates to the use of microparticles in a self-adhesive silicone gel to increase adhesion. The invention relates to a self-adhesive silicone gel that comprises microparticles and has improved adhesion properties, in particular when same also comprises additional chemical compounds/derivatives, more particularly compounds that are active, soluble or miscible in the silicone gel.

The present disclosure relates to mesoporous glasses as well as uses of such glasses, for example, as hemostats.